As night follows day, so a letter from Rep. John Dingell follows each new turn in the Vytorin saga. This morning’s WSJ reports on his latest request: Details on a study in which patients who took the cholesterol drug appeared more likely to develop cancer than patients who took placebos.
Merck and Schering-Plough, which co-market the [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment